Literature DB >> 8996396

Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue.

M S Cookson1, V E Reuter, I Linkov, W R Fair.   

Abstract

PURPOSE: Glutathione S-transferase (GST) enzymes may prevent carcinogenesis through inactivation of reactive electrophiles by conjugation to reduced glutathione. Recently, it was reported that most prostate cancers fail to express GST-pi despite an abundant presence in benign prostate tissue, suggesting a common genetic alteration. To define its presence in prostate tissue, we evaluated GST-pi expression in a variety of prostate tissues.
MATERIALS AND METHODS: Immunostaining with anti-GST-pi antibody was performed on 69 benign prostates, 44 malignant prostates, 12 incidental prostate carcinomas and 17 prostatic intraepithelial neoplasia (PIN) specimens. Specimens were evaluated for the presence and percent of GST-pi. Within benign tissue, GST-pi immunostaining was distinguished between basal cells and secretory acinar epithelium.
RESULTS: In benign epithelium, the basal cells demonstrated intense staining in all cases. The mean percent staining among the basal cells was 67% (R 40-90%). The acinar epithelium stained weakly positive in 94% (65/69) of specimens, however the mean percent staining was only 5% (R 0-25%). GST-pi was detected in only 3.5% (2/56) of the prostate cancers. No incidental prostate cancers and only one (6%) high grade PIN stained positive.
CONCLUSIONS: Our study confirms the absence of GST-pi expression in prostate cancer and high grade PIN. Furthermore, GST-pi expression correlates well with the basal cell phenotype, but not with benign epithelial cells. The lack of staining among prostate cancer cells may reflect the absence of a basal cell layer, suggesting that GST-pi is involved more in epithelial differentiation and questioning its role in the malignant transformation of prostatic acinar cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8996396

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  22 in total

1.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis.

Authors:  A M De Marzo; V L Marchi; J I Epstein; W G Nelson
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms.

Authors:  Mario Menschikowski; Albert Hagelgans; Eugene Gussakovsky; Heike Kostka; Elena L Paley; Gabriele Siegert
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

3.  Protective effect of γ-tocopherol-enriched diet on N-methyl-N-nitrosourea-induced epithelial dysplasia in rat ventral prostate.

Authors:  Lucas D Sanches; Sergio A A Santos; Jaqueline R Carvalho; Gabriela D M Jeronimo; Wagner J Favaro; Maria D G Reis; Sérgio L Felisbino; Luis A Justulin
Journal:  Int J Exp Pathol       Date:  2013-10-29       Impact factor: 1.925

4.  Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases.

Authors:  C J Henderson; A G Smith; J Ure; K Brown; E J Bacon; C R Wolf
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

Review 5.  Nervous and Neuroendocrine regulation of the pathophysiology of cholestasis and of biliary carcinogenesis.

Authors:  Marco Marzioni; Giammarco Fava; Antonio Benedetti
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

6.  Essential roles of ERKs and p38K in up-regulation of GST A1 expression by Maotai content in human hepatoma cell line Hep3B.

Authors:  Dongyun Zhang; Haitian Lu; Jingxia Li; Xianglin Shi; Chuanshu Huang
Journal:  Mol Cell Biochem       Date:  2006-06-20       Impact factor: 3.396

7.  GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells.

Authors:  X Lin; M Tascilar; W H Lee; W J Vles; B H Lee; R Veeraswamy; K Asgari; D Freije; B van Rees; W R Gage; G S Bova; W B Isaacs; J D Brooks; T L DeWeese; A M De Marzo; W G Nelson
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

8.  The effect of prostate cancer and antiandrogenic therapy on lipid peroxidation and antioxidant systems.

Authors:  Alkan Hacer Iynem; Ayşe Zeynep Alademir; Can Obek; Ali Riza Kural; Dildar Konukoğlu; Tülay Akçay
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

9.  Changes in cortical cytoskeletal and extracellular matrix gene expression in prostate cancer are related to oncogenic ERG deregulation.

Authors:  Wolfgang A Schulz; Marc Ingenwerth; Carolle E Djuidje; Christiane Hader; Jörg Rahnenführer; Rainer Engers
Journal:  BMC Cancer       Date:  2010-09-22       Impact factor: 4.430

10.  Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer.

Authors:  Antoinette S Perry; Gillian O'Hurley; Omer A Raheem; Kevin Brennan; Simon Wong; Anthony O'Grady; Anne-Marie Kennedy; Laure Marignol; Therese M Murphy; Linda Sullivan; Ciara Barrett; Barbara Loftus; John Thornhill; Stephen M Hewitt; Mark Lawler; Elaine Kay; Thomas Lynch; Donal Hollywood
Journal:  Int J Cancer       Date:  2012-09-28       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.